VBIT-4 NEW
| Price | $98 | $242 | $383 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: VBIT-4 | CAS No.: 2086257-77-2 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | VBIT-4 |
| Description | VBIT-4 is a voltage-dependent anion channel 1 (VDAC1) oligomerization inhibitor (Kd: 17 μM). VBIT-4 can be used for therapeutic purposes in apoptosis-associated disorders (such as neurodegenerative and cardiovascular diseases). |
| In vitro | VBIT-4 targets the mitochondrial protein VDAC1, inhibits apoptosis and defends against mitochondrial dysfunction. VBIT-4 (0.1-10 μM) inhibits VDAC1 oligomerization, Cyto c release from mitochondria and apoptosis (in HEK-293 cells , IC50s of 1.9±0.08 μM, 1.8±0.24 μM, and 2.9±0.12 μM, respectively).VBIT-4 offer a therapeutic strategy for treating different diseases associated with enhanced apoptosis and point to VDAC1 as a promising target for therapeutic intervention. |
| In vivo | METHODS: To test the effect on Alzheimer's disease, VBIT-4 (25 mg/kg) was injected intraperitoneally into APP/PS1 mice once daily for four weeks. RESULTS: VDAC1 was significantly up-regulated in APP/PS1 mice and decreased after VBIT-4 treatment; GPX4 expression was decreased in APP/PS1 mice and restored by VBIT-4 treatment; MWM test showed that APP/PS1 mice had a longer latency to find the plateau; VBIT-4 treatment significantly decreased the latency to find the plateau in APP/PS1 mice. VBIT-4 treatment significantly reduced the latency of platform finding in APP/PS1 mice. [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (98.28 mM), Sonication is recommended. |
| Keywords | VBIT-4 | VBIT4 | VBIT 4 |
| Inhibitors Related | Erastin | NSC 15364 | VBIT-12 | Tuvatexib | DIDS sodium salt |
| Related Compound Libraries | 經(jīng)典已知活性庫 | 膜蛋白靶向化合物庫 | 抑制劑庫 | 抗心血管疾病化合物庫 | 線粒體靶向庫 | 已知活性化合物庫 | 抗癌化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $76.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $180.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-06-05 | |
| $98.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY